A multi-center single arm phase II study of MDX-010 (BMS-734016) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Trial Profile

A multi-center single arm phase II study of MDX-010 (BMS-734016) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jun 2009 Two-year survival data was presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Bristol-Myers Squibb media release.
    • 12 Sep 2008 Updated one-year survival data will be presented at the 33rd Congress of the European Society for Medical Oncology in September.
    • 03 Jun 2008 Results presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top